FR 122047 hydrochloride
CAS: 130717-51-0
Rif. 3D-FFA71751
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione |
Informazioni sul prodotto
- Methanone, [4,5-bis(4-methoxyphenyl)-2-thiazolyl](4-methyl-1-piperazinyl)-, hydrochloride (1:1)
- Piperazine, 1-((4,5-bis(4-methoxyphenyl)-2-thiazolyl)carbonyl)-4-methyl-, monohydrochloride
- [4,5-Bis(4-methoxyphenyl)-1,3-thiazol-2-yl](4-methylpiperazin-1-yl)methanone hydrochloride (1:1)
FR 122047 hydrochloride is a novel drug that has been shown to have a pressor effect in animals. This compound also has anti-inflammatory and analgesic effects, which may be due to its ability to inhibit the production of prostaglandins. The mechanism of action of FR 122047 hydrochloride is not yet fully understood. It has been shown to bind to cannabinoid receptors in animals, but it is unclear if this is the mechanism by which it mediates its effects. FR 122047 hydrochloride has been shown to inhibit the function of caspase-8, an enzyme that plays a role in regulating the cell cycle and apoptosis. The inhibition of caspase-8 leads to increased levels of mitochondrial cytochromes, which are important for cellular respiration. FR 122047 hydrochloride has also been shown to have an inhibitory effect on platelet aggregation and antinociceptive effects in mice.
